AU2006278571B2 - Compositions exhibiting improved flowability - Google Patents

Compositions exhibiting improved flowability Download PDF

Info

Publication number
AU2006278571B2
AU2006278571B2 AU2006278571A AU2006278571A AU2006278571B2 AU 2006278571 B2 AU2006278571 B2 AU 2006278571B2 AU 2006278571 A AU2006278571 A AU 2006278571A AU 2006278571 A AU2006278571 A AU 2006278571A AU 2006278571 B2 AU2006278571 B2 AU 2006278571B2
Authority
AU
Australia
Prior art keywords
composition
powder
solid material
modified nanoparticles
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006278571A
Other languages
English (en)
Other versions
AU2006278571A1 (en
Inventor
Jimmie R. Baran Jr.
Madeline P. Shinbach
James S. Stefely
Stephen W. Stein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of AU2006278571A1 publication Critical patent/AU2006278571A1/en
Application granted granted Critical
Publication of AU2006278571B2 publication Critical patent/AU2006278571B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2006278571A 2005-08-05 2006-08-04 Compositions exhibiting improved flowability Ceased AU2006278571B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70582105P 2005-08-05 2005-08-05
US60/705,821 2005-08-05
PCT/US2006/030278 WO2007019229A1 (en) 2005-08-05 2006-08-04 Compositions exhibiting improved flowability

Publications (2)

Publication Number Publication Date
AU2006278571A1 AU2006278571A1 (en) 2007-02-15
AU2006278571B2 true AU2006278571B2 (en) 2011-11-24

Family

ID=37311861

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006278571A Ceased AU2006278571B2 (en) 2005-08-05 2006-08-04 Compositions exhibiting improved flowability

Country Status (7)

Country Link
US (1) US8062670B2 (enExample)
EP (1) EP1917301B1 (enExample)
JP (2) JP5694643B2 (enExample)
CN (1) CN101243130B (enExample)
AU (1) AU2006278571B2 (enExample)
CA (1) CA2617909C (enExample)
WO (1) WO2007019229A1 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
SI1494732T1 (sl) 2002-03-20 2008-08-31 Mannking Corp Inhalacijski aparat
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
KR100974482B1 (ko) 2003-03-27 2010-08-10 가부시키가이샤 바이오악티스 비강용 분말 약제 투약 장치
EP1785145A4 (en) * 2004-08-10 2008-08-13 Translational Res Ltd TRANSNASAL COMPOSITION WITH IMMEDIATE EFFECT AND HIGH RESORBIBILITY
JP5078014B2 (ja) 2004-08-20 2012-11-21 マンカインド コーポレイション ジケトピペラジン合成の触媒反応
JP4990142B2 (ja) 2004-08-23 2012-08-01 マンカインド コーポレイション 薬物送達のためのジケトピペラジン塩、ジケトモルホリン塩、又はジケトジオキサン塩
EP1937219B1 (en) 2005-09-14 2015-11-11 MannKind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
US20080071141A1 (en) * 2006-09-18 2008-03-20 Abhisuek Gattani Method and apparatus for measuring attributes of an anatomical feature during a medical procedure
US8236277B2 (en) * 2006-12-21 2012-08-07 3M Innovative Properties Company Process for producing nanoparticles
EP2116264B1 (en) * 2006-12-26 2017-09-27 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
CN101113078B (zh) * 2007-07-10 2011-02-02 程道远 新型玻璃防霉隔离粉
WO2009085731A1 (en) * 2007-12-21 2009-07-09 3M Innovative Properties Company Process for producing nanoparticles
DE102008020701A1 (de) * 2008-04-24 2009-10-29 Bayer Technology Services Gmbh Formulierung mit reduzierter Hygroskopizität
WO2009137595A2 (en) * 2008-05-08 2009-11-12 3M Innovative Properties Company Process for producing nanoparticles
EP2296628B1 (en) * 2008-05-22 2014-05-14 3M Innovative Properties Company Process for manufacturing flowable powder drug compositions
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN109568740B (zh) 2008-06-13 2022-05-27 曼金德公司 干粉吸入器和用于药物输送的系统
US9358352B2 (en) 2008-06-13 2016-06-07 Mannkind Corporation Dry powder drug delivery system and methods
MX336361B (es) 2008-06-20 2015-12-03 Mannkind Corp Un metodo y un aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion.
US9956170B2 (en) 2008-06-26 2018-05-01 3M Innovative Properties Company Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof
EP2309984B1 (en) * 2008-07-02 2018-04-11 3M Innovative Properties Company Method of making a dry powder pharmaceutical composition
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US20100116172A1 (en) * 2008-11-13 2010-05-13 3M Innovative Properties Company Method for making a dispersion
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
WO2010077773A1 (en) * 2008-12-30 2010-07-08 3M Innovative Properties Company Lubricant composition and method of forming
US8741819B2 (en) 2008-12-30 2014-06-03 3M Innovative Properties Company Composite particles and method of forming
EP2405963B1 (en) 2009-03-11 2013-11-06 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
US9101539B2 (en) 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
TWI547487B (zh) 2009-06-12 2016-09-01 曼凱公司 具限定比表面積之二酮基哌微粒子
US20100323067A1 (en) * 2009-06-19 2010-12-23 Hershey Foods Corporation Temperature resistant chocolate composition and method
WO2010151435A1 (en) 2009-06-26 2010-12-29 3M Innovative Properties Company Method of milling particles with nanoparticles and milled free-flowing powder
WO2011013003A2 (en) 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
US9067782B2 (en) 2009-11-20 2015-06-30 3M Innovative Properties Company Inorganic pigment compositions comprising surface-modified nanoparticles, and methods of making
CN102714071A (zh) 2009-11-20 2012-10-03 3M创新有限公司 包含其上共价连接有表面改性的纳米粒子的导电粒子的组合物、以及制备方法
US8894466B2 (en) 2009-12-03 2014-11-25 3M Innovative Properties Company Method of electrostatic deposition of particles, abrasive grain and articles
CN102639650A (zh) * 2009-12-03 2012-08-15 3M创新有限公司 通过添加疏水性纳米粒子抑制粉末吸水性的方法
CN103108830B (zh) * 2010-10-04 2014-07-16 3M创新有限公司 通过添加疏水性纳米粒子而改变粒子的溶解速率的方法
EP2651651B1 (en) * 2010-12-17 2019-01-23 3M Innovative Properties Company Transfer article having multi-sized particles and methods
SG10201606220QA (en) 2011-04-01 2016-09-29 Mannkind Corp Blister package for pharmaceutical cartridges
CN102810377A (zh) * 2011-05-31 2012-12-05 深圳出入境检验检疫局食品检验检疫技术中心 一种复合型磁性纳米的制备方法及在小分子提取及富集中的应用
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
MX2014004983A (es) 2011-10-24 2014-09-22 Mannkid Corp Metodos y composiciones para tratar dolor.
BR112014025518B1 (pt) 2012-04-13 2022-05-24 Glaxosmithkline Intellectual Property Development Limited Partículas agregadas de umeclidinium, vilanterol e fluticasona, composição em pó, inalador, processo para a preparação de partículas agregadas, e, uso de estearato de magnésio em partículas agregadas
SG10201605800UA (en) 2012-07-12 2016-09-29 Mannkind Corp Dry powder drug delivery system and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
BR112015010601B1 (pt) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
CN105517607A (zh) 2013-08-05 2016-04-20 曼金德公司 吹入设备和方法
DK3049059T3 (da) * 2013-09-24 2022-01-31 Satsuma Pharmaceuticals Inc Intranasal dhe formulering til behandlingen af hovedpine
CN104644618A (zh) * 2013-11-19 2015-05-27 上海医药工业研究院 一种干粉吸入剂及其制备方法
EP3083840A1 (en) * 2013-12-19 2016-10-26 3M Innovative Properties Company Nanoparticle powder composition and method of making the same
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
JP6546386B2 (ja) * 2014-10-15 2019-07-17 株式会社アドマテックス 無機フィラー及びその製造方法、樹脂組成物、及び成形品
WO2016064405A1 (en) 2014-10-23 2016-04-28 3M Innovative Properties Company Composition of an insulating pvc substrate with nanoparticle treated filler
KR102406867B1 (ko) 2016-06-16 2022-06-13 쓰리엠 이노베이티브 프로퍼티즈 컴파니 나노입자 충전된 배리어 접착제 조성물
TWI617533B (zh) 2016-12-09 2018-03-11 財團法人工業技術研究院 表面改質陶瓷粉體及其應用
US20180362834A1 (en) 2017-06-16 2018-12-20 TenEx Technologies, LLC Compositions And Methods For Treating Subterranean Formations
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
EP3750410A4 (en) * 2018-02-06 2021-11-10 Nisshin Foods Inc. POTATO STARCH AND POTATO STARCH COMPOSITION
WO2019180619A1 (en) 2018-03-22 2019-09-26 3M Innovative Properties Company Modified aluminum nitride particles and methods of making the same
WO2019180621A2 (en) 2018-03-22 2019-09-26 3M Innovative Properties Company Charge-modified particles and methods of making the same
EP3893877A4 (en) 2018-12-11 2022-09-14 Satsuma Pharmaceuticals, Inc. COMPOSITIONS, DEVICES AND METHODS FOR TREATMENT OR PREVENTION OF HEADACHE
EP3785825A1 (en) 2019-08-30 2021-03-03 3M Innovative Properties Company Powder blend for use in additive manufacturing
CN111358773B (zh) * 2020-04-10 2021-03-30 广州南鑫药业有限公司 一种帕拉米韦干粉吸入剂及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2801185A (en) 1952-05-16 1957-07-30 Du Pont Silica hydrosol powder
US4478876A (en) 1980-12-18 1984-10-23 General Electric Company Process of coating a substrate with an abrasion resistant ultraviolet curable composition
US4491508A (en) 1981-06-01 1985-01-01 General Electric Company Method of preparing curable coating composition from alcohol, colloidal silica, silylacrylate and multiacrylate monomer
US4455205A (en) 1981-06-01 1984-06-19 General Electric Company UV Curable polysiloxane from colloidal silica, methacryloyl silane, diacrylate, resorcinol monobenzoate and photoinitiator
US4486504A (en) 1982-03-19 1984-12-04 General Electric Company Solventless, ultraviolet radiation-curable silicone coating compositions
US4522958A (en) 1983-09-06 1985-06-11 Ppg Industries, Inc. High-solids coating composition for improved rheology control containing chemically modified inorganic microparticles
US4767726A (en) 1987-01-12 1988-08-30 Minnesota Mining And Manufacturing Company Glass microbubbles
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5037579A (en) 1990-02-12 1991-08-06 Nalco Chemical Company Hydrothermal process for producing zirconia sol
US5258225A (en) 1990-02-16 1993-11-02 General Electric Company Acrylic coated thermoplastic substrate
AU701603B2 (en) 1994-04-25 1999-02-04 Minnesota Mining And Manufacturing Company Compositions comprising fused particulates and methods of making them
DE19616781A1 (de) 1996-04-26 1997-11-06 Degussa Silanisierte Kieselsäure
CA2365412C (en) 1997-12-22 2002-09-17 Schering Corporation Orally administrable solid ribavirin dosage forms and process for making them
US6329058B1 (en) 1998-07-30 2001-12-11 3M Innovative Properties Company Nanosize metal oxide particles for producing transparent metal oxide colloids and ceramers
GB9822523D0 (en) * 1998-10-15 1998-12-09 Courtaulds Coatings Holdings Powder coating compositions
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US6585957B1 (en) * 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
US7758888B2 (en) * 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
NZ526059A (en) * 2000-11-30 2005-05-27 Vectura Ltd Method of making composite active particles in the presence of an additive material for use in a pharmaceutical composition
US6586483B2 (en) 2001-01-08 2003-07-01 3M Innovative Properties Company Foam including surface-modified nanoparticles
CN1263808C (zh) * 2001-02-27 2006-07-12 清华大学 一种微米颗粒表面纳米化改性方法
ES2292848T3 (es) * 2001-10-12 2008-03-16 Elan Pharma International Limited Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada.
US7923030B2 (en) * 2003-03-14 2011-04-12 Sol-Gel Technologies, Inc. Agent-encapsulating micro- and nanoparticles, methods for preparation of same and products containing same
US7459146B2 (en) * 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions

Also Published As

Publication number Publication date
JP2013100352A (ja) 2013-05-23
EP1917301B1 (en) 2014-04-23
WO2007019229A1 (en) 2007-02-15
AU2006278571A1 (en) 2007-02-15
CA2617909C (en) 2014-02-04
JP2009503104A (ja) 2009-01-29
CN101243130A (zh) 2008-08-13
CN101243130B (zh) 2011-12-07
JP5694643B2 (ja) 2015-04-01
US8062670B2 (en) 2011-11-22
EP1917301A1 (en) 2008-05-07
US20080286362A1 (en) 2008-11-20
CA2617909A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
AU2006278571B2 (en) Compositions exhibiting improved flowability
EP2309978B1 (en) Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof
EP2296628B1 (en) Process for manufacturing flowable powder drug compositions
EP2309984B1 (en) Method of making a dry powder pharmaceutical composition
CA2195065C (en) Inhalation composition
CN1913873B (zh) 包含装在防水容器中的tiotropium的医学产品
US7459146B2 (en) Stabilized aerosol dispersions
AP1374A (en) Aerosolizable particles resistant to hygroscopic growth.
PL186757B1 (pl) Proszek do stosowania w suchym inhalatorze proszkowym i sposób wytwarzania proszku do stosowania w suchym inhalatorze proszkowym
CN101098671A (zh) 最少化表面上的粉末滞留量
Vanderbist et al. Optimization of a dry powder inhaler formulation of nacystelyn, a new mucoactive agent
Ong The aerosol performance and physico-chemical properties of co-milled dry powder formulations for high dose delivery

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired